Jul. 28, 2015, 5:35 PM
- ACGL, AEGN, AEL, AEM, AFFX, ALGT, ANIK, AR, ARII, ARRS, ASGN, ASH, ATW, BANC, BAX, BKCC, BLKB, BXP, CAVM, CBL, CEMP, CGI, CHDN, CHMT, CLD, CMO, CMPR, CNO, CNW, CROX, CSGP, CW, CWT, CXO, DDR, DOX, DRE, DYAX, EHTH, ELY, EQIX, EQY, ESRT, ESV, EXR, FARO, FB, FBP, FICO, FISV, FMI, FNF, FOE, FORM, FORR, HLS, HOLX, HOS, HY, IPCM, ISIL, IXYS, KEG, KEX, KGC, KRA, KRG, KS, LNC, LOCK, LPSN, LRCX, MAA, MANT, MAR, MC, MCK, MDAS, MEOH, MET, MMLP, MTGE, MTW, MUR, NBIX, NE, NOW, NSIT, NTRI, NXPI, O, OGS, OI, ORLY, OTEX, PDM, PEGA, PEIX, PPC, PSA, PTC, PVA, QGEN, QUIK, RKUS, ROG, RRTS, SBAC, SCI, SCTY, SFLY, SGMO, SKX, SPRT, SSNC, SSS, STAA, SU, TAL, TER, THG, THRM, THRX, TILE, TTEK, UNM, VAR, VGR, VNDA, VRTX, WDC, WES, WFM, WGP, WLL, WMB, WMGI, WSTL, WTS, WYNN
Jul. 7, 2015, 8:11 AM
- The FDA designates Dyax's (NASDAQ:DYAX) investigational fully human monoclonal antibody inhibitor of plasma kallikrein (pKAL), DX-2930, a Breakthrough Therapy for the treatment of hereditary angioedema (HAE). Uncontrolled pKAL activity leads to excessive generation of bradykinin, a vasodilator believed to play a key role in localized swelling, inflammation and pain associated with HAE.
- HAE is a rare acute inflammatory condition characterized by episodes of severe, painful swelling of the extremities, GI tract, genitalia and larynx. It is caused by abnormally low levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits pKAL. HAE affects ~1 in 50,000 people.
- Breakthrough Therapy status provides for more intensive guidance from the FDA, the involvement of more senior agency staff and a rolling review of the New Drug Application (NDA).
Jun. 11, 2015, 7:59 AM
- RBC Capital Markets' Michael Yee says (NASDAQ:DYAX) would be a juicy acquisition for the likes of Sanofi (NYSE:SNY), Alexion Pharmaceuticals (NASDAQ:ALXN) or BioMarin Pharmaceutical (NASDAQ:BMRN). He thinks the takeout price could be as high as $39 per share or 59% above yesterday's close of $24.53.
- Dyax's allure pertains to its investigational drug for hereditary angioedema (HAE), Fast Track-designated DX-2930, which has performed well in early-stage studies. The only approved therapy for HAE is Shire's (NASDAQ:SHPG) Cinryze [C1 esterase inhibitor (human)] which costs as much as $630K per year. Its on track to be Shire's #2 seller in two years.
- Previously: Dyax +39.1% on positive DX-2930 trial results (March 31)
- Previously: Dyax scores Orphan designation for HAE treatment (Dec. 5, 2013)
May 15, 2015, 12:32 PM
- Edwards Lifesciences (EW +0.2%) upgraded to Overweight from Neutral with a $155 (18% upside) price target by JP Morgan.
- Anthera Pharmaceuticals (ANTH -2.2%) upgraded to Neutral from Sell by Citigroup.
- Aerie Pharmaceuticals (AERI) upgraded to Buy from Hold with a $15 (36% upside) price target by Cantor Fitzgerald.
- Cutera (CUTR +1.8%) upgraded to Overweight from Neutral with a $17 (21% upside) price target by Piper Jaffray.
- Cesca Therapeutics (KOOL -5.9%) downgraded to Neutral from Buy by H.C. Wainwright.
- Clovis Oncology (CLVS -7.1%) downgraded to Neutral from Overweight with $100 (6% upside) price target maintained by Piper Jaffray.
- Health Insurance Innovations (HIIQ +0.9%) downgraded to Neutral from Buy by Bank of America.
- Humana (HUM +0.1%) downgraded to Underperform from Neutral with a $150 (14% downside risk) price target by Sterne Agee CRT.
- Dyax (DYAX -0.2%) downgraded to Market Perform from Outperform by Oppenheimer.
- MannKind (MNKD +9.6%) downgraded to Underweight from Neutral by JP Morgan.
- Fluidigm (FLDM -2.2%) downgraded to Neutral from Buy with $30 (20% upside) price target by Mizuho Securities.
Apr. 29, 2015, 4:12 PM
- Dyax (NASDAQ:DYAX): Q1 EPS of -$0.05 in-line.
- Revenue of $20.4M (+44.5% Y/Y) misses by $1.39M.
Apr. 28, 2015, 5:35 PM
- AEL, AFFX, AR, ARII, ARRS, ASGN, ASH, ATRC, ATW, AVG, AXS, BIDU, BLKB, BVN, CACI, CAVM, CBT, CHMT, CMO, CMPR, CNO, CNW, COHR, CRL, CSGP, CSII, CW, CWT, DOX, DRE, DXCM, DYAX, ECOL, ELGX, EQIX, EQY, ES, ESV, EXL, EXR, FLEX, FOE, FORM, FORR, GLUU, HOLX, HOS, HY, IPCM, ISIL, KAMN, KEG, KEX, KRA, LNC, LOCK, LOPE, LXRX, MAA, MAC, MANT, MAR, MDAS, MEOH, MEP, MMLP, MTGE, MTW, MUR, NE, NSR, NXPI, O, OGS, OIS, PDM, PPC, PRXL, PTC, QEP, QUIK, RKT, ROG, RRTS, SAM, SCI, SFLY, SGI, SPOK, SPRT, SSS, STAA, STR, SU, TAL, TCO, TEX, TILE, TTEK, TTMI, TX, UNM, VAR, VRTX, WLL, WMB, WMGI, WTS, XL, YELP
Apr. 13, 2015, 4:02 PM
Apr. 8, 2015, 6:58 AM
- (NASDAQ:DYAX) prices its public offering of 7.4M shares of common stock at $27 per share. Underwriters over-allotment is an additional 1.11M shares. Closing date is April 13. Net proceeds will fund the development and commercialization of DX-2930 for the prophylactic treatment of hereditary angioedema, R&D projects, the repayment of the loan with LFRP Investors, L.P. and general corporate purposes.
Apr. 6, 2015, 5:35 PM
Apr. 6, 2015, 4:07 PM
- (NASDAQ:DYAX) commences a public offering of 7M shares of common stock. Underwriters over-allotment is an additional 1.05M shares. Price and terms have yet to be announced.
Apr. 1, 2015, 12:45 PM
Apr. 1, 2015, 9:13 AM
Mar. 31, 2015, 5:36 PM
Mar. 31, 2015, 4:45 PM
- Dyax (NASDAQ:DYAX) +35.7% AH after announcing positive results from a Phase 1b clinical trial of its DX-2930 investigational product for the prevention of hereditary angioedema attacks.
- Dyax says primary proof-of-concept efficacy analyses were based on subjects in the 300 mg, 400 mg, and placebo dose groups who reported having at least two attacks in the three months prior to study entry; the company says DX-2930 was well tolerated at all dose levels.
- Dyax also says it received Fast Track designation from the FDA for the investigation of DX-2930 for prevention of hereditary angioedema attacks.
Mar. 5, 2015, 8:52 AM
- AbbVie's (NYSE:ABBV) extraordinarily generous buyout of Pharmacyclics (NASDAQ:PCYC) is a crystal clear example of how keen big pharma is to boost its prospects with biotech drugs with blockbuster potential. The transaction's $20B tab, backing out PCYC's $1B cash balance, values Imbruvica (ibrutinib) at $40B since Pharmacyclics' commercial partner Johnson & Johnson (NYSE:JNJ) gets 50% of Imbruvica's revenue. This implies a multiple of almost 7x Imbruvica's projected peak sales of $6B. By comparison, Amgen's (NASDAQ:AMGN) takeout of Onyx Pharma and Sanofi's (NYSE:SNY) takeout of Genzyme were both at 5x premiums.
- The looming patent expiration for Humira ($12.5B in sales the past four quarters) undoubtedly provided AbbVie extra incentive to get the deal done.
- Adding 50% of Imbruvica's sales to AbbVie's top line should increase its revenue growth 3 - 7% and EPS growth 8 - 11% through 2020.
- According to RBC analyst Michael Yee, other biotechs on the big ticket acquisition radar are: BioMarin Pharmaceuticals (NASDAQ:BMRN), Dyax (NASDAQ:DYAX), Esperion Therapeutics (NASDAQ:ESPR), United Therapeutics (NASDAQ:UTHR), Vertex Pharmaceuticals (NASDAQ:VRTX), Intercept Pharmaceuticals (NASDAQ:ICPT), Juno Therapeutics (NASDAQ:JUNO), Kite Pharma (NASDAQ:KITE), PTC Therapeutics (NASDAQ:PTCT) and Receptos (NASDAQ:RCPT).
Feb. 24, 2015, 7:02 AM
- Dyax (NASDAQ:DYAX): Q4 EPS of -$0.02 beats by $0.02.
- Revenue of $26M (+54.2% Y/Y) beats by $6.1M.
Dyax Corp is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated (PKM)Disorders and Licensing and Funded Research Portfolio.
Country: United States
Other News & PR